Docket Room.
SB 435·MD·senate

Public Health - Medetomidine and Xylazine Consumer Protection Act

FailedFiled Jan 30, 2026
Sponsor: Folden
Latest Action

Motion Laid Over (Senator Ready) Adopted (Senate)

Apr 13, 2026

Email me when SB 435 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track SB 435. By continuing you agree to the Terms and Privacy Policy.

Summary

The bill bars any retailer from selling or displaying medetomidine or xylazine products unless the purchaser shows proof the drug will be used for institutional, veterinary, or scientific purposes and is at least 21 years old. Retailers must keep records of the age verification and the intended‑use documentation, and violations carry civil fines that go to the Maryland Substance Abuse Fund. The law aims to curb misuse of these substances and protect public health.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about SB 435

3 free questions a day, no account

Hearings

History

  1. Motion Laid Over (Senator Ready) Adopted
  2. Favorable with Amendments Report by Finance
  3. Favorable with Amendments {
  4. Hearing 2/11 at 2:00 p.m.
  5. First Reading Finance

Sponsors

  • Folden · sponsor

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when SB 435 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track SB 435 free

Or ask your AI assistant about SB 435 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice